World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2026
Volume: 5; Issue: 1
Page: 216-218

CHURNA YIELD-BASED COMPARISON: IMPACT OF RAW DRUG VARIABILITY ON AYURVEDIC PHARMACEUTICAL STANDARDISATION

Dr. Bibin K. B.*

PhD (Scholar) Shri Jagadishprasad Jhabarmal Tibrewala University.

Article Received: 19 November 2025 | | ***Article Revised: 9 December 2025*** | | ***Article Accepted: 29 December 2025***

***Corresponding Author: Dr. Bibin K. B.**
PhD (Scholar) Shri Jagadishprasad Jhabarmal Tibrewala University.
DOI: https://doi.org/10.5281/zenodo.18109366

How to cite this Article: Dr. Bibin K. B. (2026) AYURVEDA IN ACTION: A CASE STUDY ON SUCCESSFUL CONCEPTION THROUGH COUPLE-BASED INFERTILITY MANAGEMENT. World Journal of Pharmaceutical Science and Research, 5(1), 216-218. https://doi.org/10.5281/zenodo.18109366

ABSTRACT

In Ayurveda, Churna (medicinal powders) are one of the most basic ways to give medicine, and they are still widely used in both traditional medicine and modern pharmacy practice. The output from raw drug materials has a big impact on the quality, effectiveness, and cost-effectiveness of Churna formulas. There is a lot of variation in Churna yield because of changes in the natural qualities of the drugs and outside factors like where they come from, the weather, when they are harvested, and how they are stored. Variability like this makes it hard to be consistent and standardised from batch to batch when making Ayurvedic medicines. This piece takes a critical look at the things that affect Churna yield, talks about what those things mean for pharmaceuticals, and stresses how important it is to combine yield-based assessment with well-known quality control standards. A lot of attention is paid to how the quality of the raw drug, handling losses, and regulatory standards affect the consistency and treatment effectiveness of Churna formulations.

KEYWORDS: Churna, Yield variation, Raw drug quality, Ayurvedic pharmaceutics, Standardisation.

1. INTRODUCTION

Churna, or medicinal powders, are one of the most ancient and extensively employed dose forms in the Ayurvedic medical system. Their ease of preparation, versatility in administration, and suitability as both independent formulations and intermediates for other dosage forms ensure their ongoing significance in modern practice. Churna formulations, though seemingly simple, need stringent pharmaceutical accuracy, as their quality and performance are directly affected by the properties of the basic medicinal ingredients utilised.

Yield, defined as the ultimate quantity of Churna derived from a certain amount of raw medication, is a critical yet sometimes undervalued statistic in Ayurvedic pharmacological research. Yield variations influence both the economic feasibility of manufacturing and reveal fundamental disparities in raw drug quality, processing efficiency, and handling procedures. In extensive production, even slight decreases in yield can lead to significant financial losses, whereas artificially enhanced yields may jeopardise product quality.

Due to the growing focus on evidence-based Ayurveda, regulatory adherence, and worldwide recognition of traditional medicines, a systematic assessment of yield variability has become imperative. This article seeks to examine the determinants affecting Churna yield, emphasising raw drug variability and its consequences for pharmaceutical standardisation.

2. Concept of Yield in Churna Preparation

The yield of Churna denotes the proportion of fine, acceptable powder acquired following the processes of washing, drying, pulverising, and screening the raw medicinal material. Yield loss frequently arises from the elimination of extraneous materials, moisture reduction, rejection of coarse particles, and losses incurred during milling and handling processes. Yield, while a quantitative metric, indirectly indicates qualitative characteristics of the raw medicine, such as purity, structural integrity, and physicochemical composition.

3. Role of Raw Drug Quality in Churna Yield

3.1 Intrinsic Properties of Raw Drugs

The inherent characteristics of raw pharmaceuticals considerably affect Churna yield.

- **Moisture Content:** Pharmaceuticals with elevated intrinsic moisture content exhibit increased weight loss during the drying process, leading to diminished ultimate yield.
- **Fibrous or Woody Composition:** Dense and lignified substances, such as heartwoods, provide challenges in achieving the necessary particle size, resulting in elevated rejection rates during sieving.
- **Volatile Constituents:** Pharmaceuticals abundant in volatile oils may experience mass loss during grinding and storage, hence impacting both yield and therapeutic efficacy.

3.2 Extrinsic Factors Affecting Raw Drug Quality

Factor	Effect on Raw Drug Composition	Impact on Churna Yield
Geographical distribution	Variation in secondary metabolites	Inconsistency in bulk powder yield
Climatic conditions	Changes in moisture, ash, and extractive values	Reduced yield after drying or processing
Period of harvesting	Variations in maturity and structural integrity	Increased rejection or foreign matter
Storage conditions	Moisture absorption, fungal growth, and infestation	Direct loss of usable raw drug

Table showing the total yield in fine Churna form of different raw materials

S. No.	Raw Drug Quantity (kg)	Churna Obtained (kg)	Yield (%)	Machine used
1	Ashwagandha-120kg	91.0	75.83 %	Pulveriser
2	Shatavari -25kg	20.9	83.6%	Pulveriser
3	Yashtimadhu-79.3kg	56.6	71.37%	Pulveriser
4	Shatapushpa -3kg	2.0	66.66%	Industrial Mixer Grinder
5	Mandukaparni- 10kg	7.0	70.0%	Pulveriser
6	Shunti-15kg	14.18	94.5%	Pulveriser
7	Haridra-19.22kg	16.1	83.76%	Pulveriser

8	Pippali -14kg	7.16	51.14%	Pulveriser
9	Lavanga-4kg	3.35	83.75%	Industrial Mixer Grinder
10	Twak -9.15kg	5.6	61.02%	Pulveriser
11	Tejapatra-5kg	3.75	75.0%	Pulveriser
12	Maricha-8.83kg	7.8	88.33%	Pulveriser
13	Ajmoda-10.2kg	8.86	86.86%	Industrial Mixer Grinder
14	Amalaki-30 kg	16.5	55.0%	Pulveriser
15	Jeeraka-5kg	3.3	66.0%	Industrial Mixer Grinder
16	Arjuna- 20kg	16.8	84.0%	Pulveriser
17	Misreya-11kg	7.9	71.8%	Pulveriser

4. Comparative Analysis of Churna Yield

The yield of Churna indicates the ratio of fine, acceptable powder obtained after washing, drying, pulverising, and screening the raw pharmaceutical material. Yield loss sometimes occurs due to the removal of unwanted materials, moisture reduction, rejection of coarse particles, and losses sustained during milling and handling operations. Yield, albeit a quantitative measure, indirectly reflects qualitative attributes of the raw medication, including purity, structural integrity, and physicochemical composition.

5. Implications for Standardisation and Quality Control

Yield variability highlights the necessity for rigorous standardisation protocols. Verification of raw pharmaceuticals, elimination of extraneous substances, determination of ash values, and analysis of extractive values according to the Ayurvedic Pharmacopoeia of India (API) are crucial for ensuring satisfactory production and therapeutic effectiveness. Yield assessment should be combined with pharmacognostic and physicochemical evaluations rather than regarded in isolation.

6. CONCLUSION

A yield-based analysis of Churna formulations indicates that the quality of the raw medication is a crucial factor influencing production efficiency and product uniformity. Although yield is a straightforward quantitative metric, the factors affecting it are multifaceted and intricate. The use of Good Agricultural and Collection Practices (GACP), stringent quality control measures, and methodical yield assessment are crucial for the production of standardised, efficacious, and economically sustainable Churna formulations in contemporary Ayurvedic medicinal practice.

REFERENCES

1. Sarangadhara. *Sarngadhara Saṃhita*, Madhyama Khanda.
2. Agnivesa. *Charaka Saṃhita*, Vimana Sthana.
3. Susruta. *Susruta Saṃhita*, Sutra Sthana.
4. Bhavamisra. *Bhavaprakasa Nighaṇṭu*.
5. Government of India. *Ayurvedic Pharmacopoeia of India*. Ministry of AYUSH.
6. World Health Organisation. *WHO Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants*.
7. Kokate CK, Purohit AP, Gokhale SB. *Pharmacognosy*. Nirali Prakashan.
8. Evans WC. *Trease and Evans Pharmacognosy*. Elsevier.